APY TherapeuticsAPY Therapeutics LLC is developing arylmyxopyronins--APYs--as novel first-in-class IV-oral treatments for lower-respiratory-tract infections caused by drug-resistant and multi-drug-resistant Gram-negative bacteria, Gram-positive bacteria, and respiratory atypicals.